Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.37 CAD 1.97% Market Closed
Market Cap: 313.1m CAD

Profound Medical Corp
Change in Deffered Taxes

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Profound Medical Corp
Change in Deffered Taxes Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Deffered Taxes CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Change in Deffered Taxes
-$139k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Ondine Biomedical Inc
LSE:OBI
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Conavi Medical Corp
XTSX:CNVI
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
313.1m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
HIDDEN
Show

See Also

What is Profound Medical Corp's Change in Deffered Taxes?
Change in Deffered Taxes
-139k USD

Based on the financial report for Sep 30, 2025, Profound Medical Corp's Change in Deffered Taxes amounts to -139k USD.

Back to Top